Oligonucleotides for use in detecting coronavirus (SARS-CoV-2) and detection method thereof

Specific oligonucleotides labeled with intercalating fluorescent dyes and designed for SARS-CoV-2 detection address the limitations of existing methods by providing rapid and sensitive detection with high specificity, reducing false positives.

JP7589458B2Active Publication Date: 2024-11-26TOSOH CORP
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
JP2020120834
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Filing Date
2020-07-14
Publication Date
2024-11-26
Estimated Expiration
2040-07-14

AI Technical Summary

Technical Problem

Existing methods for detecting SARS-CoV-2 are either time-consuming and require skilled operators or lack sensitivity and specificity, leading to false positives, especially in distinguishing it from other coronaviruses.

Method used

Development of specific oligonucleotides, including those labeled with intercalating fluorescent dyes, that can rapidly and sensitively amplify and detect SARS-CoV-2 RNA by forming complementary double strands, using primer sets with sequences from SEQ ID NOs 6 and 13, and employing nucleic acid amplification methods like RT-PCR.

Benefits of technology

The oligonucleotides enable rapid and specific detection of SARS-CoV-2 with minimal false positives, allowing for prompt test results and effective infection control.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007589458000001
    Figure 0007589458000001
  • Figure 0007589458000002
    Figure 0007589458000002
  • Figure 0007589458000003
    Figure 0007589458000003
Patent Text Reader

Abstract

To provide detection methods to specifically amplify 2019 novel coronavirus (SARS-CoV-2) present in samples with little possibility of false-positive.SOLUTION: SARS-CoV-2 is detected by using an oligonucleotide that detects a nucleic acid derived from 2019 novel coronavirus (SARS-CoV-2) or complementary sequence thereof. The oligonucleotide comprises a sequence of contiguous ten or more bases selected from the base sequence of a certain sequence or complementary sequence thereof.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to an oligonucleotide for rapid, highly sensitive and specific detection of the 2019 novel coronavirus (hereinafter referred to as SARS-CoV-2) contained in a sample, and a method for detecting SARS-CoV-2 using the oligonucleotide. [Background technology]

[0002] The novel coronavirus disease (hereafter referred to as COVID-19) is caused by the SARS-CoV-2 virus and was identified in Wuhan, Hubei Province, People's Republic of China in 2019. The World Health Organization (WHO) declared COVID-19 a "Public Health Emergency of International Concern (PHEIC)." Subsequently, on March 11, 2020, based on the global spread of infection and the severity of the disease, it was announced that COVID-19 could be considered a pandemic (global epidemic).

[0003] Coronaviridae are positive-sense single-stranded RNA (ribonucleic acid) viruses with an envelope of 80 to 160 nm in diameter, which infect various animals such as dogs, pigs, cattle, and camels in addition to humans. They are classified into genera α, β, γ, and δ based on genetic characteristics. Viruses that mainly cause cold syndrome in humans include the 229E and NL63 strains of the αcoronavirus genus, and the OC43 and HKU1 strains of the βcoronavirus genus. These four viruses account for 10 to 15% of colds (35% during epidemics). In addition to these, SARS (severe acute respiratory syndrome) coronavirus was identified in 2003, and MERS (Middle East respiratory syndrome) coronavirus was identified in 2012. Both of these coronaviruses cause severe infectious diseases in humans, mainly pneumonia, and the mortality rate is very high, about 10% for the former and over 30% for the latter (Non-Patent Document 1). SARS-CoV-2 belongs to the same βcoronavirus as SARS and MERS. Based on complete base sequence analysis and phylogenetic tree analysis, SARS-CoV-2 shares 75-80% homology with SARS coronavirus and 85-88% homology with bat coronaviruses. For this reason, SARS-CoV-2 is believed to have originated from a bat virus.

[0004] Initial symptoms are mild, including fever, fatigue, dry cough, loss of appetite, muscle pain, difficulty breathing, phlegm, and sore throat, and may include loss of smell and taste. In severe cases, pneumonia may develop. Initial symptoms usually last for about 5 to 7 days, and will gradually improve if they do not become severe.

[0005] If the condition worsens, breathing becomes difficult. In addition to pneumonia, inflammation of other respiratory organs, such as upper respiratory tract infection and bronchitis, may also be observed. Even if severe pneumonia occurs, it will gradually recover by treating the symptoms, but if it worsens and becomes serious, it may cause acute respiratory syndrome (ARDS), septic shock, multiple organ failure, and in some cases, death.

[0006] In normal viral infections, the likelihood of infecting others is highest when symptoms are most pronounced, but it is believed that COVID-19 patients can be infected when they are asymptomatic, when they are in a mild stage, or when they are in a severe stage. In particular, identifying asymptomatic pathogen carriers who are infected with the virus and can infect others without showing symptoms is of utmost importance in preventing the spread of infection and in-hospital infections. In addition, large-scale screening tests are considered effective in identifying asymptomatic individuals, and a test method with sufficient processing capacity and high sensitivity is required.

[0007] Highly sensitive testing methods include genetic testing methods that amplify and detect viral nucleic acids. However, the process of extracting viral nucleic acids from samples is complicated, and a certain level of training is required from the operator to obtain reliable results. In addition, it takes time to obtain results, and the method lacks speed. On the other hand, antigen-antibody testing methods are characterized by their simplicity, high processing capacity, and high speed, but their sensitivity is not as high as that of genetic testing, and there is a possibility of false negatives.

[0008] The TRC method used in the present invention (Patent Document 2, Patent Document 3) is commercially available with an integrated device that performs everything from purification to detection, and can provide results in about one hour, making it sufficiently rapid. In addition, the sensitivity and specificity are comparable to other nucleic acid amplification detection methods.

[0009] Because the nucleic acid to be amplified for the new coronavirus (SARS-CoV-2) has a high base sequence homology with other coronaviruses, it has been extremely difficult to design primer sets and oligonucleotide probes that can detect the gene with high sensitivity and specificity. It has been particularly difficult to distinguish it from the coronavirus (SARS-CoV) that was prevalent in 2003. When using an amplification method that can amplify RNA under relatively low constant temperature conditions (e.g., 40°C to 50°C), the nucleic acid to be amplified is more likely to form a higher-order structure, making it even more difficult to design the primer set and oligonucleotide probe. [Prior art documents] [Patent documents]

[0010] [Patent Document 1] JP 2009-131174 A [Patent Document 2] JP 2000-14400 A [Patent Document 3] JP 2001-37500 A [Non-patent literature]

[0011] [Non-Patent Document 1] Wang C, et al: A novel coronavirus outbreak of global health concern. Lancet 395: 470-473, 2020. doi: 10.1016 / S0140-6736(20)30185-9. Summary of the Invention [Problem to be solved by the invention]

[0012] The object of the present invention is to provide a specific oligonucleotide that can amplify nucleic acid derived from the novel coronavirus (SARS-CoV-2) present in a sample with high sensitivity and rapid amplification while reducing the occurrence of false positives, and a method for detecting the novel coronavirus (SARS-CoV-2) using the oligonucleotide. [Means for solving the problem]

[0013] The present inventors have conducted intensive research to solve the above problems and have completed the present invention.

[0014] (1) An oligonucleotide for detecting the 2019 novel coronavirus (SARS-CoV-2), characterized in that it consists of a sequence of 10 or more consecutive bases selected from the base sequence set forth in SEQ ID NO:1 or its complementary sequence. (2) The oligonucleotide according to claim 1, characterized in that the oligonucleotide (1) is an oligonucleotide labeled with a fluorescent dye and configured such that its fluorescent properties change when it forms a complementary double-stranded chain. (3) The oligonucleotide according to claim 2, characterized in that the oligonucleotide (2) is labeled with an intercalative fluorescent dye.

[0015] (4) A method for detecting the 2019 novel coronavirus (SARS-CoV-2), characterized by using the oligonucleotide described in (1). (5) The detection method according to (4), characterized in that the oligonucleotide according to (2) is used. (6) The detection method according to (5), wherein the oligonucleotide is labeled with an intercalative fluorescent dye. (7) The detection method according to any one of (4) to (6), characterized in that a pair of primer set is used. (8) The detection method described in (7), characterized in that the primer set comprises a first primer consisting of a sequence of 10 or more consecutive bases selected from the base sequence set forth in SEQ ID NO: 6 or its complementary sequence, and a second primer consisting of a sequence of 10 or more consecutive bases selected from the base sequence set forth in SEQ ID NO: 13 or its complementary sequence. (9) The detection method according to (8), characterized in that the first primer consists of 15 to 30 consecutive bases in the base sequence set forth in SEQ ID NO: 6 or its complementary sequence, and the second primer consists of 15 to 30 consecutive bases in the base sequence set forth in SEQ ID NO: 13 or its complementary sequence. Effect of the Invention

[0016] The oligonucleotides of the present invention can specifically detect the base sequence of the RNA of the novel coronavirus (SARS-CoV-2) or its complementary sequence by hybridizing to a portion of the sequence specific to the RNA of the novel coronavirus (SARS-CoV-2) and its complementary sequence.

[0017] The oligonucleotide of the present invention and the method for detecting the novel coronavirus (SARS-CoV-2) using the oligonucleotide can rapidly and sensitively detect the novel coronavirus (SARS-CoV-2) contained in a sample, and has high specificity with extremely low false positives, e.g., it does not detect other coronavirus species. Therefore, it is possible to promptly present the test results to doctors, which is thought to contribute to preventing the spread of infection and early improvement of symptoms by administering appropriate drugs. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0018] The present invention will be described in detail below.

[0019] In the present invention, the sample may be a nasopharyngeal swab, sputum, bronchoalveolar lavage fluid, tracheal aspirate, pleural effusion, blood, urine, stool, or the like.

[0020] The detection of a nucleic acid containing the nucleic acid base sequence of the RNA of the novel coronavirus (SARS-CoV-2) or its complementary sequence using the oligonucleotide of the present invention can be performed using a conventionally known nucleic acid detection method. (A) Methods using electrophoresis or liquid chromatography, (B) Hybridization methods using oligonucleotide probes labeled with a detectable label; (C) a method using a fluorescent dye-labeled oligonucleotide that is designed to change its fluorescence characteristics by hybridizing with a part of the base sequence of an amplification product obtained by amplifying a nucleic acid containing the specific base sequence or its complementary sequence using a set of primers; Examples of the fluorescent dye-labeled oligonucleotide (C) include a fluorescent dye-labeled oligonucleotide that utilizes FRET (fluorescence resonance energy transfer) and an oligonucleotide labeled with an intercalating fluorescent dye.

[0021] An example of the oligonucleotide labeled with the intercalating fluorescent dye is an oligonucleotide that is specifically hybridizable with a part of a nucleic acid containing the base sequence of RNA of the novel coronavirus (SARS-CoV-2) or its complementary sequence, and that is labeled with an intercalating fluorescent dye via a suitable linker at the 3'-end, 5'-end, phosphodiester part, or base part of the oligonucleotide. When the oligonucleotide forms a complementary double strand with the base sequence (or its complementary sequence) of RNA of the novel coronavirus (SARS-CoV-2), the intercalating fluorescent dye part intercalates into the complementary double strand part, changing the fluorescent properties. There is no particular limitation on the intercalating fluorescent dye to be labeled, and it may be appropriately selected from among commonly used fluorescent dyes such as oxazole yellow, thiazole orange, ethidium bromide, and hemicyanine, and their derivatives, taking into consideration the fluorescent intensity and fluorescent properties. Except when labeling the 3'-end with a fluorescent dye, the 3'-end of the oligonucleotide may be appropriately modified with glycolic acid or the like to prevent a nucleic acid extension reaction from the end.

[0022] An example of an oligonucleotide constituting the oligonucleotide labeled with the intercalative fluorescent dye is an oligonucleotide that can specifically hybridize with a nucleic acid containing a base sequence of RNA possessed by the novel coronavirus (SARS-CoV-2) or its complementary sequence, and that contains a consecutive base sequence of at least 10 bases in the base sequence set forth in SEQ ID NO: 1 or its complementary sequence. More preferred are oligonucleotides capable of hybridizing to the nucleotide sequence set forth in SEQ ID NO: 2 (the nucleotide sequence from base 29212 to base 29228 of GenBank No. MN908947.1) or its complementary sequence, oligonucleotides capable of hybridizing to the nucleotide sequence set forth in SEQ ID NO: 3 (the nucleotide sequence from base 29216 to base 29235 of GenBank No. MN908947.1) or its complementary sequence, oligonucleotides capable of hybridizing to the nucleotide sequence set forth in SEQ ID NO: 4 (the nucleotide sequence from base 29228 to base 29245 of GenBank No. MN908947.1) or its complementary sequence, and oligonucleotides capable of hybridizing to the nucleotide sequence set forth in SEQ ID NO: 5 (the nucleotide sequence from base 29239 to base 29258 of GenBank No. MN908947.1) or its complementary sequence.

[0023] Examples of hybridization conditions for the oligonucleotide and its complementary sequence in the present invention include conditions at 42°C in the presence of 50% (v / v) formamide, 0.1% bovine serum albumin, 0.1% ficoll, 0.1% polyvinylpyrrolidone, 50 mM sodium phosphate buffer (pH 6.5), 150 mM sodium chloride, and 75 mM sodium citrate, and nucleic acid amplification conditions described in the Examples of this specification. In addition, as long as the base sequence of the RNA of the novel coronavirus (SARS-CoV-2) can be hybridized sufficiently specifically and efficiently under the conditions, the base sequences of the first and second primers may have substitutions, deletions, additions, or modifications compared to the specific base sequence. The length of the first and second primers can be set arbitrarily, but is preferably in the range of 10 to 50 bases.

[0024] The present invention is characterized by using an oligonucleotide capable of specifically hybridizing to the nucleotide sequence set forth in SEQ ID NO: 6 (the nucleotide sequence from bases 29135 to 29206 of GenBank No. MN908947.1) as a first primer having a sequence complementary to the 5' end of the nucleotide sequence of RNA of the novel coronavirus (SARS-CoV-2) contained in the sample, and using an oligonucleotide capable of specifically hybridizing to the nucleotide sequence set forth in SEQ ID NO: 13 (the nucleotide sequence from bases 29280 to 29396 of GenBank No. MN908947.1) as a second primer having a sequence homologous to the 3' end of the nucleotide sequence of RNA of the novel coronavirus (SARS-CoV-2) contained in the sample.

[0025] Among these, it is preferable that the first primer and the second primer each consist of 15 to 30 bases.

[0026] An example of the first primer is an oligonucleotide consisting of 15 to 30 consecutive bases in the nucleotide sequence set forth in SEQ ID NO: 6 or its complementary sequence. More specific examples include SEQ ID NO: 7 (complementary sequence of the nucleotide sequence from 29135 to 29154 in GenBank No. MN908947.1), SEQ ID NO: 8 (complementary sequence of the nucleotide sequence from 29142 to 29161 in GenBank No. MN908947.1), SEQ ID NO: 9 (complementary sequence of the nucleotide sequence from 29155 to 29174 in GenBank No. MN908947.1), SEQ ID NO: 10 (complementary sequence of the nucleotide sequence from 29166 to 29185 in GenBank No. MN908947.1), SEQ ID NO: 11 (complementary sequence of the nucleotide sequence from 29179 to 29196 in GenBank No. MN908947.1) and SEQ ID NO: 12 (complementary sequence of the nucleotide sequence from 29179 to 29196 in GenBank No. MN908947.1). An example of such an oligonucleotide is an oligonucleotide having the base sequence set forth in the above (the complementary sequence of the base sequence from base 29187 to base 29206 of No. MN908947.1).

[0027] An example of the second primer is an oligonucleotide consisting of 15 to 30 consecutive bases in the base sequence set forth in SEQ ID NO: 13 or its complementary sequence. More specific examples of the second primer include SEQ ID NO: 14 (the base sequence from base 29280 to base 29299 in GenBank No. MN908947.1), SEQ ID NO: 15 (the base sequence from base 29295 to base 29310 in GenBank No. MN908947.1), SEQ ID NO: 16 (the base sequence from base 29307 to base 29326 in GenBank No. MN908947.1), SEQ ID NO: 17 (the base sequence from base 29324 to base 29342 in GenBank No. MN908947.1), SEQ ID NO: 18 (the base sequence from base 29340 to base 29359 in GenBank No. MN908947.1), and SEQ ID NO: 19 (the base sequence from base 29351 to base 29359 in GenBank No. MN908947.1). Examples of such oligonucleotides include oligonucleotides having the nucleotide sequence set forth in SEQ ID NO: 20 (the nucleotide sequence from base 29359 to base 29381 of GenBank No. MN908947.1), SEQ ID NO: 20 (the nucleotide sequence from base 29365 to base 29387 of GenBank No. MN908947.1), and SEQ ID NO: 21 (the nucleotide sequence from base 29373 to base 29396 of GenBank No. MN908947.1).

[0028] Among these, from the viewpoint of being capable of rapidly and specifically detecting RNA possessed by the novel coronavirus (SARS-CoV-2), a primer set in which the first primer is an oligonucleotide consisting of a nucleotide sequence set forth in any one of SEQ ID NOs: 7, 8, 9, 10, 11, and 12, and the second primer is an oligonucleotide consisting of a nucleotide sequence set forth in any one of SEQ ID NOs: 14, 15, 16, 17, 18, 19, 20, and 21, is preferred. Among these, a primer set in which the combination of the first primer and the second primer is an oligonucleotide consisting of a nucleotide sequence set forth in any one of SEQ ID NOs: 8 and 20, 10 and 20, 10 and 14, 10 and 17, 10 and 19, or 10 and 21 is even more preferred.

[0029] The primer set of the present invention is useful as a primer set for amplifying a nucleic acid containing a base sequence of RNA of the novel coronavirus (SARS-CoV-2) or its complementary sequence, using a nucleic acid amplification method commonly used by those skilled in the art, such as RT-PCR. In addition, if an RNA polymerase promoter is further added to the 5'-end of either the first or second primer, a nucleic acid containing a base sequence to which an RNA polymerase promoter has been added or its complementary sequence is synthesized using an RNA polymerase corresponding to the promoter, and therefore, it is preferable in that RNA can be amplified from these nucleic acids using a method for amplifying RNA at a constant temperature, such as NASBA (Nucleic Acid Sequence Based Amplification) method, TMA (Transcription-Mediated Amplification) method, or TRC (Transcription-Reverse Transcription Concerted Reaction) method. The promoter added to the 5'-end of the primer may be a promoter corresponding to the RNA polymerase used for RNA amplification (for example, T7 RNA polymerase, T3 RNA polymerase, or SP6 RNA polymerase, which are commonly used in the field of molecular biology). In addition, a transcription initiation region that is known to affect transcription efficiency may be further added to the promoter. When T7 RNA polymerase is used as the RNA polymerase for RNA amplification, a specific example of the promoter (T7 promoter) to be added to the 5'-end side of the primer is an oligonucleotide having the sequence shown in SEQ ID NO:24.

[0030] To detect RNA present in the novel coronavirus (SARS-CoV-2) using the oligonucleotide of the present invention, the detection can be carried out, for example, by the steps shown in (1) to (6) below.

[0031] (1) a step in which a second primer, which is an oligonucleotide capable of specifically hybridizing to the nucleotide sequences set forth in SEQ ID NOs: 13 to 23 or their complementary sequences, hybridizes to an RNA possessed by the novel coronavirus (SARS-CoV-2), and an enzyme having RNA-dependent DNA polymerase activity synthesizes a cDNA complementary to the specific nucleotide sequence to generate an RNA-DNA double strand with the RNA; (2) decomposing the RNA of the RNA-DNA double strand with an enzyme having ribonuclease H (RNase H) activity (producing single-stranded DNA); (3) hybridizing a first primer, which is an oligonucleotide capable of specifically hybridizing to the nucleotide sequence of any one of SEQ ID NOs: 6 to 12 or its complementary sequence, to the single-stranded DNA (wherein either the first or second primer has an RNA polymerase promoter added to its 5'-end side), and generating a double-stranded DNA containing a promoter capable of transcribing RNA of the nucleotide sequence of the amplified region or its complementary sequence by an enzyme having DNA-dependent DNA polymerase activity; (4) producing an RNA transcription product using the double-stranded DNA as a template with an enzyme having RNA polymerase activity; (5) a step in which the RNA transcription product serves as a template for cDNA synthesis in the reaction of (1) above, thereby producing an RNA transcription product in a chain reaction; (6) A process of measuring the amount of the RNA transcript over time using an oligonucleotide containing SEQ ID NO:1 or its complementary sequence, the oligonucleotide being capable of hybridizing to the RNA or its complementary sequence possessed by the novel coronavirus (SARS-CoV-2) and labeled with an intercalating fluorescent dye.

[0032] The enzyme having RNA-dependent DNA polymerase activity used in the step (1), the enzyme having RNase H activity used in the step (2), and the enzyme having DNA-dependent DNA polymerase activity used in the step (3) can be added separately or in various combinations, but a reverse transcriptase derived from a retrovirus having both of the above activities can also be used. The reverse transcriptase is not particularly limited, and examples of the reverse transcriptase that can be used include AMV (Avian Myeloblastosis Virus) reverse transcriptase, MMLV (Molony Murine Leukemia Virus) reverse transcriptase, RAV (Rous Associated Virus) reverse transcriptase, and HIV (Human Immunodeficiency Virus) reverse transcriptase, which are commonly used in the field of molecular biology.

[0033] The reaction temperature in the method for detecting RNA possessed by the novel coronavirus (SARS-CoV-2) according to the above-mentioned embodiment depends on the heat resistance and activity of each enzyme used, as well as the Tm of the primers / probes, etc. However, when the enzymes used are AMV reverse transcriptase and T7 RNA polymerase, and the length of the primers / probes is in the range of 15 to 20 bases, the reaction temperature can be set in the range of 35 to 65°C, and it is more preferable to set it in the range of 40 to 50°C.

[0034] The method for detecting RNA contained in the novel coronavirus (SARS-CoV-2) in the above-mentioned manner measures fluorescence intensity over time, so that the measurement can be terminated at any time when a significant increase in fluorescence is observed, and the nucleic acid amplification and measurement can usually be completed within 20 minutes.

[0035] In the method for detecting the RNA of the novel coronavirus (SARS-CoV-2) according to the above-mentioned embodiment, a sample is added to a reagent for detecting the novel coronavirus (SARS-CoV-2) RNA, which contains the above-mentioned first primer, second primer, and an oligonucleotide labeled with an intercalating fluorescent dye, and the sample is placed on a temperature-control block capable of detecting fluorescence over time, thereby automatically amplifying and detecting the RNA of the novel coronavirus (SARS-CoV-2). The oligonucleotide for detecting the RNA of the novel coronavirus (SARS-CoV-2) of the present invention is preferably one consisting of the base sequences shown in SEQ ID NOs: 2 to 4. EXAMPLES

[0036] The present invention will be described in detail below with reference to examples, but the present invention is not limited to these examples.

[0037] Example 1 Preparation of oligonucleotides labeled with fluorescent intercalating dyes

[0038] The oligonucleotide labeled with a fluorescent intercalating dye (hereinafter referred to as INAF probe) shown in (A) below was prepared based on the method disclosed in JP-A-2000-316587.

[0039] (A) An oligonucleotide consisting of the nucleotide sequence set forth in SEQ ID NO: 2 (the nucleotide sequence from bases 29212 to 29228 of GenBank No. MN908947.1) or its complementary sequence, the nucleotide sequence set forth in SEQ ID NO: 3 (the nucleotide sequence from bases 29216 to 29235 of GenBank No. MN908947.1) or its complementary sequence, the nucleotide sequence set forth in SEQ ID NO: 4 (the nucleotide sequence from bases 29228 to 29245 of GenBank No. MN908947.1) or its complementary sequence, or the nucleotide sequence set forth in SEQ ID NO: 5 (the nucleotide sequence from bases 29239 to 29258 of GenBank No. MN908947.1) or its complementary sequence, wherein the 12th thymine from the 5'-end in SEQ ID NO: 2, the 8th thymine from the 5'-end in SEQ ID NO: 3, the 8th cytosine from the 5'-end in SEQ ID NO: 4, and the 5th cytosine from the 5'-end in SEQ ID NO: 5 are labeled with thiazole orange via a linker.

[0040] Example 2: Examination of oligonucleotides for detecting the new coronavirus (SARS-CoV-2)

[0041] Evaluation was performed by the method described below using the combinations of the first primer, second primer, and INAF probe (hereinafter, referred to as oligonucleotide combinations) shown in Table 1. The INAF probe shown in Table 1 is the probe prepared in Example 1.

[0042] (1) A commercially available control reagent (AMPLIRUN SARS-CoV-2 RNA CONTROL, vircell) was used as the RNA for the novel coronavirus (SARS-CoV-2). The control RNA was diluted to 1000 copies / 15 μL using RNA diluent (10 mM Tris-HCl buffer (pH 8.0), 1 mM EDTA, 0.02% sodium cholate), and these were used as RNA samples.

[0043] (2) A reaction solution having the following composition was dispensed into an evaporation drying tube and evaporated to dryness. Composition of reaction solution: Concentrations of RNA sample, starting solution, and final concentration after addition (in 30 μL) 60mM Tris-HCl buffer (pH8.35) 300mM Trehalose 0.39mM each dATP, dCTP, dGTP, dTTP 2.1mM each of ATP, CTP, and UTP 1.5mM GTP 3.2mM ITP 0.4μM first primer 0.4 μM second primer (an oligonucleotide consisting of the base sequence of each sequence number to which a T7 promoter (SEQ ID NO: 24) has been added at the 5' end) 10 nM INAF probe (prepared in Example 1) 0.025mg / mL bovine serum albumin 200U T7 RNA polymerase 9.0U AMV reverse transcriptase

[0044] (3) After the above evaporation and drying, 15 μL of the RNA sample was added and incubated at 46° C. for 5 minutes, after which 15 μL of a starting solution having the following composition was added and stirred. Composition of enzyme solution: Final concentration during reaction (in 30 μL) 9.00% Dimethyl sulfoxide 21mM Magnesium chloride 137mM Potassium Chloride

[0045] (4) The evaporative drying tube was then reacted at 46°C using a thermostatically controlled fluorescence spectrophotometer capable of direct measurement, and the fluorescence intensity of the reaction solution was measured over time for 20 minutes.

[0046] The time when the starting solution was added and stirring was completed was set to 0 minutes, and a positive judgment was made when the fluorescence intensity ratio of the reaction solution (fluorescence intensity value at a specified time divided by the background fluorescence intensity ratio) exceeded 1.5, and the time at this point was taken as the detection time. The results are shown in Tables 1, 2, and 3. The experiment was performed twice for each combination, and the average value was used. "ND" means that the fluorescence intensity ratio 20 minutes after the start of the reaction was 1.5 or less (negative judgment).

[0047] Regarding the detection performance of SARS-CoV-2 RNA (Table 1), among the oligonucleotide combinations (set 1 to set 21) examined in this example, all of them, except for sets 10 to 13, 15, and 18, detected 1000 copies / test of SARS-CoV-2 RNA within 20 minutes. In particular, oligonucleotide combinations set 1 to 3, set 5 to 8, set 14, set 17, and 20 detected 1000 copies / test of SARS-CoV-2 RNA within 10 minutes on average, and can be said to be oligonucleotide combinations capable of rapidly detecting SARS-CoV-2 RNA.

[0048] [Table 1]

[0049] Among the oligonucleotide combinations examined in this example, set 2 and set 6 were used to evaluate the measurement sensitivity (Table 2) and cross-reactivity with other coronavirus RNA (Table 3), among which the detection time was within 10 minutes.

[0050] Regarding the measurement sensitivity of the novel coronavirus (SARS-CoV-2) RNA, 30 copies / test of the novel coronavirus (SARS-CoV-2) RNA was detected, and regarding cross-reactivity, 2003 SARS (SARS-CoV), MERS, and coronaviruses (229E, OC43) were not detected, showing high specificity for the novel coronavirus (SARS-CoV-2). The oligonucleotide combination examined in this example can be said to be a combination of oligonucleotides capable of specifically detecting the RNA possessed by the novel coronavirus (SARS-CoV-2).

[0051] [Table 2]

[0052] [Table 3]

Claims

1. An oligonucleotide and a set of primers for detecting the 2019 novel coronavirus (SARS-CoV-2), comprising: The primer set includes a first primer that is an oligonucleotide having a base sequence set forth in any one of SEQ ID NOs: 7, 8, and 10, and a second primer that is an oligonucleotide having a base sequence set forth in any one of SEQ ID NOs: 14, 17, 19, 20, 21, and 23, The detection oligonucleotide has a sequence selected from the base sequence set forth in any one of SEQ ID NOs: 2, 3, and 4, or a complementary sequence thereof. A detection oligonucleotide and a set of primers.

2. The detection oligonucleotide and a pair of primer set described in claim 1, characterized in that the detection oligonucleotide is an oligonucleotide labeled with a fluorescent dye and configured to change its fluorescent properties when it forms a complementary double-stranded strand.

3. 3. The set of detection oligonucleotide and primer according to claim 2, wherein the detection oligonucleotide is labeled with an intercalative fluorescent dye.

4. The detection oligonucleotide and a pair of primer sets described in claim 1, wherein the combination of the first primer and the second primer is a primer set which is an oligonucleotide consisting of a base sequence described in any one of SEQ ID NOs: 8 and 20, 10 and 20, 10 and 14, 10 and 17, 10 and 19, 10 and 21, or 10 and 23.

5. A method for detecting the 2019 novel coronavirus (SARS-CoV-2), comprising using the detection oligonucleotide and a pair of primer sets described in claim 1.

6. The detection method according to claim 5, characterized in that the detection oligonucleotide according to claim 2 is used.

7. The detection method according to claim 6, wherein the detection oligonucleotide is labeled with an intercalative fluorescent dye.

8. The detection method described in claim 5, characterized in that the combination of the first primer and the second primer uses the primer set described in claim 4.

Citation Information

Patent Citations

  • Novel coronavirus SARS-CoV-2 fluorescence quantitative PCR detection method and applications thereof

    CN111394513A

  • Determination of target nucleic acid

    JP2000014400A

  • Determination of nucleic acid

    JP2001037500A

  • Method for detecting mycoplasma pneumoniae

    JP2009131174A

  • Nucleic acid amplification method and nucleic acid amplifying reagent

    JP2019106986A